Comparative Pharmacology
Head-to-head clinical analysis: DURLAZA versus PLAVIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DURLAZA versus PLAVIX.
DURLAZA vs PLAVIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Durlaza (aspirin) irreversibly acetylates cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), inhibiting thromboxane A2 synthesis and reducing platelet aggregation.
Clopidogrel is a prodrug that is converted to an active metabolite by CYP450 enzymes. The active metabolite selectively inhibits the P2Y12 component of ADP receptors on the platelet surface, which prevents ADP-mediated activation of the glycoprotein GPIIb/IIIa complex, thereby inhibiting platelet aggregation.
325 mg orally once daily
75 mg orally once daily, with or without food. For acute coronary syndrome, a loading dose of 300 mg (or 600 mg for PCI) is given followed by 75 mg daily.
None Documented
None Documented
2-4 hours (prolonged in renal impairment; up to 10-20 hours in severe impairment). Clinical dosing adjustments required when CrCl <30 mL/min.
Clopidogrel parent: ~6 hours; active thiol metabolite: ~30 minutes; terminal half-life of inactive metabolite(s): ~8 hours. Clinically, platelet inhibition persists for 5–7 days due to irreversible P2Y12 receptor binding.
Primarily renal (70-80% as unchanged drug), with 10-15% biliary/fecal. Negligible hepatic metabolism.
Renal: ~50% as inactive metabolites; biliary/fecal: ~50% as inactive metabolites.
Category C
Category C
Antiplatelet Agent
Antiplatelet Agent